This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A combination of CBL0137 and panobinostat has been demonstrated to effectively treat neuroblastoma in mice. This combination therapy has the potential to lead the fight against this aggressive childhood cancer.
An international team has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells.
A valuable cache of brain cancer biomedical data, termed REMBRANDT, has been made freely accessible to researchers worldwide.
A proof-of-concept study reveals that silibinin may reduce brain metastasis in mice and patients, providing a potential treatment option for secondary brain tumors.
For World Brain Tumor Day (8 June), Gene Barnett, a neurosurgeon at the Cleveland Clinic (OH, USA) discusses common perceptions around brain tumors and their work with ‘tumor-treating fields’.
Interim results from a Phase III trial of DCVax®-L have revealed that the vaccine could be safe in glioblastoma patients and may extend survival.
This week, our industry report covers neuroblastoma, DUB inhibitors for neurodegenerative diseases and pediatric multiple sclerosis.
In partnership with The Brain Tumour Charity, the Cancer Research UK Brain Tumour Awards hope to tackle six major themes in brain tumor research.